Alvin Lopez-Pujals, MD
Urology · Caguas, PRNPI 1750334835
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,800 of the $27,176 with a category attached, or 61.8%. Boston Scientific accounts for 74.2% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $10,431 and has fallen 83.0% since, to $1,770 in 2025.
Across 137 payments — averaging $198.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$20K
- Teleflex LLC$2K
- Profound Medical Corp.$925
- Olympus Corporation Of The Americas$811
- Verity Pharmaceuticals Inc.$726
- Johnson & Johnson$500
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$16,80062%
- Travel & lodging$4,40716%
- Food & beverage$5,78421%
- Education$1851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 39 | $20,166 |
| Teleflex LLC | 5 | $1,616 |
| Profound Medical Corp. | 12 | $925 |
| Olympus Corporation Of The Americas | 4 | $811 |
| Verity Pharmaceuticals Inc. | 7 | $726 |
| Johnson & Johnson(2 entities) | 21 | $500 |
| Medtronic | 9 | $342 |
| Olympus Latin America, Inc. | 3 | $311 |
| Ferring Pharmaceuticals Inc. | 6 | $276 |
| Travere Therapeutics, Inc. | 3 | $248 |
| Merck | 4 | $183 |
| BD | 3 | $174 |
| Stryker | 3 | $157 |
| Progenics Pharmaceuticals, Inc. | 1 | $124 |
| PBG Puerto Rico LLC | 5 | $114 |
| Neotract Inc. | 1 | $112 |
| AbbVie | 4 | $104 |
| Pfizer | 1 | $100 |
| Astellas Pharma US Inc | 1 | $85 |
| Tolmar, Inc. | 3 | $70 |
| Pfizer Pharmaceuticals LLC | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$17,506
- UroLift$1,642
- Olympus Resection Disposables$768
- Tulsa-Pro$484
- TRELSTAR$447
- VISERA ELITE$302
- GENERAL BPH$256
- INTERSTIM$251
- TLANDO$245
- AMS 700 CXR RTE KIT$139
- (815) Thiola$130
- Soltive$130
- Proxis Ureteral Access Sheath$130
- ADSTILADRIN$128
- KEYTRUDA$124
- PYLARIFY$124
- rezum Generator$100
How this compares
$27,176 in reported general payments places this provider in the 85th percentile of 122 urology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrelstarTriptorelin Pamoate | 137 | $132,675 |
| MyrbetriqMirabegron | 59 | $27,411 |
| Tamsulosin Hcl | 2,338 | $19,434 |
| Tolterodine Tartrate ErTolterodine Tartrate | 349 | $16,575 |
| Finasteride | 1,437 | $13,592 |
| Potassium Citrate ErPotassium Citrate | 91 | $4,960 |
| Ciprofloxacin Hcl | 588 | $4,349 |
| Bicalutamide | 85 | $2,478 |
| Silodosin | 54 | $2,407 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 169 | $1,889 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 194 | $1,819 |
| Dutasteride | 58 | $1,338 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 45 | $1,119 |
| Sildenafil Citrate | 79 | $1,024 |
| Bethanechol Chloride | 22 | $1,003 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Verity Pharmaceuticals Inc.Trelstar | $726 | $132,675137 claims |
| Astellas Pharma US IncMyrbetriq | $85 | $27,41159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 122 urology providers in Puerto Rico.
Other urology in Caguas
- Antonio Yulian ValentinCaguas$48K
- Ramon Ramos CartagenaCaguas$5K
- Timoteo Torres SantiagoCaguas$4K
- Claudio Bernaschina BobadillaPonce$132K
- Mariela Martinez-RiveraPonce$105K
- Freddy Mendez TorresCayey$95K
- Luis AmbertRio Piedras$64K
- Jorge Crespo CarrilloRio Piedras$62K
- Ronald Cadillo ChavezBayamon$61K
- Andres Perez RomanSan Juan$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.